Funk F - Search Results

1

Tissue biodistribution of intravenous iron-carbohydrate nanomedicines differs between preparations with varying physicochemical characteristics in an anemic rat model.

Funk F, Weber K, Nyffenegger N, Fuchs JA, Barton A. Funk F, et al. Eur J Pharm Biopharm. 2022 May;174:56-76. doi: 10.1016/j.ejpb.2022.03.006. Epub 2022 Mar 23. Eur J Pharm Biopharm. 2022. PMID: 35337966

2

The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose.

Funk F, Ryle P, Canclini C, Neiser S, Geisser P. Funk F, et al. Arzneimittelforschung. 2010;60(6a):345-53. doi: 10.1055/s-0031-1296299. Arzneimittelforschung. 2010. PMID: 20648926 Review.

3

Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose.

Neiser S, Rentsch D, Dippon U, Kappler A, Weidler PG, Göttlicher J, Steininger R, Wilhelm M, Braitsch M, Funk F, Philipp E, Burckhardt S. Neiser S, et al. Among authors: funk f. Biometals. 2015 Aug;28(4):615-35. doi: 10.1007/s10534-015-9845-9. Epub 2015 Mar 24. Biometals. 2015. PMID: 25801756

4

Criticality of Surface Characteristics of Intravenous Iron-Carbohydrate Nanoparticle Complexes: Implications for Pharmacokinetics and Pharmacodynamics.

Funk F, Flühmann B, Barton AE. Funk F, et al. Int J Mol Sci. 2022 Feb 15;23(4):2140. doi: 10.3390/ijms23042140. Int J Mol Sci. 2022. PMID: 35216261 Free PMC article. Review.

5

Kupffer Cells and Blood Monocytes Orchestrate the Clearance of Iron-Carbohydrate Nanoparticles from Serum.

Arsiwala T, Vogt AS, Barton AE, Manolova V, Funk F, Flühmann B, Bachmann MF. Arsiwala T, et al. Among authors: funk f. Int J Mol Sci. 2022 Feb 28;23(5):2666. doi: 10.3390/ijms23052666. Int J Mol Sci. 2022. PMID: 35269805 Free PMC article.

6

Correction: Funk et al. Criticality of Surface Characteristics of Intravenous Iron-Carbohydrate Nanoparticle Complexes: Implications for Pharmacokinetics and Pharmacodynamics. Int. J. Mol. Sci. 2022, 23, 2140.

Funk F, Flühmann B, Barton AE. Funk F, et al. Int J Mol Sci. 2022 Sep 6;23(18):10230. doi: 10.3390/ijms231810230. Int J Mol Sci. 2022. PMID: 36142898 Free PMC article.

7

Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation.

Floege J, Funk F, Ketteler M, Rastogi A, Walpen S, Covic AC, Sprague SM. Floege J, et al. Among authors: funk f. Nephrol Dial Transplant. 2020 Jun 1;35(6):946-954. doi: 10.1093/ndt/gfaa030. Nephrol Dial Transplant. 2020. PMID: 32259248 Free PMC article.

8

The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro.

Wilhelm M, Gaillard S, Rakov V, Funk F. Wilhelm M, et al. Among authors: funk f. Clin Nephrol. 2014 Apr;81(4):251-8. doi: 10.5414/cn108119. Clin Nephrol. 2014. PMID: 24656315

9

Renoprotective effects of sucroferric oxyhydroxide in a rat model of chronic renal failure.

Neven E, Corremans R, Vervaet BA, Funk F, Walpen S, Behets GJ, D'Haese PC, Verhulst A. Neven E, et al. Among authors: funk f. Nephrol Dial Transplant. 2020 Oct 1;35(10):1689-1699. doi: 10.1093/ndt/gfaa080. Nephrol Dial Transplant. 2020. PMID: 33022710 Free PMC article.

10

Interactions between iron(III)-hydroxide polymaltose complex and commonly used medications / laboratory studies in rats.

Funk F, Canclini C, Geisser P. Funk F, et al. Arzneimittelforschung. 2007;57(6A):370-5. doi: 10.1055/s-0031-1296685. Arzneimittelforschung. 2007. PMID: 17691586

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

99 results

Search Page

Filters